Changes in biomarkers of cardiovascular risk after a switch to abacavir in HIV-1-infected individuals receiving combination antiretroviral therapy

HIV Medicine

Volumn 10, Issue 10, 2009, Pages 627-633

  Kristoffersen, U S ^a,b   Kofoed, K ^c   Kronborg, G ^c   Benfield, T ^c   Kjaer, A ^a,b   Lebech, A M ^c  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Abacavir; Cardiovascular disease; High sensitivity C reactive protein; HIV; Matrix metallopeptidase; Myeloperoxidase; Soluble intercellular adhesion molecule 1; Soluble vascular cell adhesion molecule 1

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIDANOSINE; EFAVIRENZ; GELATINASE B; INDINAVIR; INTERCELLULAR ADHESION MOLECULE 1; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NEVIRAPINE; SAQUINAVIR; STAVUDINE; TENOFOVIR; VASCULAR CELL ADHESION MOLECULE 1; ZIDOVUDINE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LONGITUDINAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VIRUS LOAD;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LONGITUDINAL STUDIES; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PEROXIDASE; RISK FACTORS; VASCULAR CELL ADHESION MOLECULE-1; VIRAL LOAD; ZIDOVUDINE;

EID: 70449389022     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00733.x     Document Type: Article

References (29)

1. d'Arminio Monforte A, Sabin CA, Phillips AN. Cardio- and cerebrovascular events in HIV-infected persons. AIDS 2004, 18:1811-1817.
2. Friis-Moller N, Sabin CA, Weber R. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349:1993-2003.
3. Friis-Moller N, Reiss P, Sabin CA. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007, 356:1723-1735.
4. Holmberg SD, Moorman AC, Williamson JM. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002, 360:1747-1748.
5. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003, 17:2479-2486.
6. Sabin CA, Worm SW, Weber R. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D Study. Lancet 2008, 371:1417-1426.
7. Cutrell A, Brothers C, Yeo J, Hernandez J, Lapierre D. Abacavir and the potential risk of myocardial infarction. Lancet 2008, 371:1413.
8. Lundgren JD, Neuhaus J, Babiker A. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008, 22:F17-F24.
9. Mulvihill NT, Foley JB, Murphy R, Crean P, Walsh M. Evidence of prolonged inflammation in unstable angina and nonQ wave myocardial infarction. J Am Coll Cardiol 2000, 36:1210-1216.
10. Blankenberg S, Rupprecht HJ, Bickel C. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001, 104:1336-1342.
11. O'Malley T, Ludlam CA, Riemermsa RA, Fox KA. Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1); potential risk factor for the acute coronary syndromes. Eur Heart J 2001, 22:1226-1234.
12. Hwang SJ, Ballantyne CM, Sharrett AR. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. Circulation 1997, 96:4219-4225.
13. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998, 351:88-92.
14. Hlatky MA, Ashley E, Quertermous T. Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. Am Heart J 2007, 154:1043-1051.
15. Timms PM, Mannan N, Hitman GA. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype. QJM 2002, 95:787-796.
16. Zhang R, Brennan ML, Fu X. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001, 286:2136-2142.
17. Brennan ML, Penn MS, Van LF. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003, 349:1595-1604.
18. Baldus S, Heeschen C, Meinertz T. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003, 108:1440-1445.
19. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation 1997, 96:4204-4210.
20. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
21. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
22. Cutrell AG, Hernandez JE, Fleming JW. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother 2004, 38:2171-2172.
23. Hetherington S, McGuirk S, Powell G. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001, 23:1603-1614.
24. Mallal S, Phillips E, Carosi G. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008, 358:568-579.
25. Phillips EJ. Genetic screening to prevent abacavir hypersensitivity reaction. Clin Infect Dis 2006, 43:103-105.
26. Shikuma CM, Ribaudo HJ, Zheng E. 96-week effects of suppressive efavirenz-containing ART, abacavir, and sex on high-sensitivity C-reactive protein: ACTG A5095. . Montreal, Canada, February 2009 [Abstract 736].
27. McComsey GA, Smith KY, Patel P. Similar reductions in markers of inflammation and endothelial activation after initiation of abacavir/lamivudine or tenofovir/emtricitabine: the HEAT Study. . Montreal, Canada, February 2009 [Abstract 732].
28. Palella F, Tracy R, Jacobson L. Inflammatory markers among abacavir and non-abacavir recipients in the women's interagency HIV study and the multicenter AIDS cohort study. . Montreal, Canada, February 2009 [Abstract 150 LB].
29. Moyle GJ, Sabin CA, Cartledge J. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006, 20:2043-2050.